Lanreotide Acetate Injection
Product Images NDC 69097-870

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Lanreotide Acetate (NDC 69097-870). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lanreotide Acetate 01)

Chemical structure of lanreotide acetate illustrating the peptide sequence with disulfide bonds and variable acetic acid substitution (x = 1.0 to 2.0). The structure depicts key amino acid residues and the molecular conformation of the active ingredient.*

FDA Label Image

Figure 1 (Lanreotide Acetate 02)

A Kaplan-Meier survival curve showing progression-free survival probability (%) over time in months for two groups: Somatuline Depot (lanreotide acetate) and placebo. The graph includes a risk table with the number of subjects at risk at different time points and statistical data for hazard ratio (HR=0.47), 95% confidence interval, and p-value (<0.001).*

FDA Label Image

Fig 1 (Lanreotide Acetate 03)

An instructional diagram showing components of a syringe and needle pack. The needle pack includes a green needle shield, green collar, needle cap, lid, and contains the needle inside. The syringe consists of a barrel, plunger, and cap. The diagram is labeled as Figure 1.*

FDA Label Image

Fig 2 (Lanreotide Acetate 04)

An instructional illustration showing three components related to a needle pack for Lanreotide Acetate injection: a clear needle cap, a needle with a green retractable shield (needle visible through a round window), and the final assembly labeled as a needle pack containing the needle inside.*

FDA Label Image

Fig 3 (Lanreotide Acetate 05)

An instructional illustration showing two hands holding a syringe with a green needle shield. The text advises not to touch the green needle shield, stating it is not a cap, with a red X over the hand near the shield.*

FDA Label Image

Fig 4 (Lanreotide Acetate 06)

An instructional illustration showing how to administer a subcutaneous injection using a syringe. The left side depicts pressing the plunger of the syringe, with an arrow indicating downward movement. The right side shows the syringe barrel in place. A red clock icon with '20 sec' indicates the recommended injection duration.*

FDA Label Image

Fig 5 (Lanreotide Acetate 07)

An instructional illustration showing a vial labeled with 60 mg of medication, likely a dosage form of lanreotide acetate injection. Next to the vial is a timer displaying 30 minutes, possibly indicating an administration or preparation time for a subcutaneous injection.*

FDA Label Image

Fig 6 (Lanreotide Acetate 08)

An instructional diagram showing the proper and improper injection sites for Lanreotide Acetate injection. The left side illustrates the correct injection area on the upper outer quadrant of the buttock, marked 'OK.' The right side shows an incorrect injection area marked with a red X, indicating to avoid injecting near the spine or central buttock region.*

FDA Label Image

Fig 7 (Lanreotide Acetate 09)

An instructional illustration showing a vial labeled with Tranexamic 60 mg and a timer displaying 30:00 minutes, indicating a 30-minute preparation or waiting period for the dose before administration.*

FDA Label Image

Fig 8 (Lanreotide Acetate 10)

An instructional illustration showing hands being washed under a running faucet with water flowing from the tap into a sink basin. The image emphasizes proper handwashing technique as part of a procedural step.*

FDA Label Image

Fig 9 (Lanreotide Acetate 11)

Figure 4 is a black-and-white line illustration showing a close-up view of a label on the Lanreotide Acetate injection packaging. The label text includes the product name "Lanreotide Acetate" and some additional information, with a magnified inset highlighting part of the label's detail. The image is likely part of an instructional or regulatory document describing the packaging or labeling.*

FDA Label Image

Fig 10 (Lanreotide Acetate 12)

An instructional diagram showing proper injection sites for Lanreotide Acetate subcutaneous injection. It depicts two views: a standing person with injection sites on the upper outer areas of the buttocks marked 'OK', and a person lying down with the same buttock areas labeled as appropriate injection sites.*

FDA Label Image

Fig 11 (Lanreotide Acetate 13)

An anatomical illustration showing the lower back and buttocks area, highlighting two injection sites marked "OK" on the upper outer quadrant of each buttock. The figure demonstrates appropriate subcutaneous injection locations for Lanreotide Acetate.*

FDA Label Image

Fig 12 (Lanreotide Acetate 14)

An instructional line drawing illustrating the subcutaneous injection site on the upper outer thigh. The image shows a hand holding a small packet or pad against the skin, indicating preparation or post-injection care for the Lanreotide Acetate injection.*

FDA Label Image

Fig 13 (Lanreotide Acetate 15)

An instructional illustration showing a person removing or handling a packaged Lanreotide Acetate injection syringe. The image demonstrates the removal of a sealed syringe pouch, likely as part of preparation for subcutaneous injection.*

FDA Label Image

Fig 14 (Lanreotide Acetate 16)

An instructional line drawing showing a pair of hands holding a syringe or prefilled injection device. One hand is pulling back on the plunger while the other hand holds the syringe barrel, demonstrating preparation or use of the injection. The figure is labeled as Figure 9, likely part of step-by-step administration instructions.*

FDA Label Image

Fig 15 (Lanreotide Acetate 17)

An instructional illustration showing hands operating a prefilled syringe, demonstrating how to unlock or prepare the injection device prior to subcutaneous administration of lanreotide acetate injection.*

FDA Label Image

Fig 16 (Lanreotide Acetate 18)

An instructional illustration showing two hands preparing a syringe. The syringe components labeled are the barrel held in the left hand and the plunger held in the right hand, indicating interaction between them likely for medication administration or preparation.*

FDA Label Image

Fig 17 (Lanreotide Acetate 19)

An instructional illustration showing two hands preparing an injection. One hand holds a syringe with a green stopper, and the other hand is removing a cap from the syringe, indicated by an arrow pointing away from the syringe. The figure is labeled "Figure 12."*

FDA Label Image

Fig 18 (Lanreotide Acetate 20)

An instructional illustration showing hands holding a syringe with a green needle shield. Text instructs not to touch the green needle shield, indicating it is not a cap. The figure is labeled as Figure 13, demonstrating proper syringe handling technique for Lanreotide Acetate injection.*

FDA Label Image

Fig 19 (Lanreotide Acetate 21)

An instructional diagram labeled 'Figure 14' depicting a hand pressing on the skin of the upper buttocks area, demonstrating the proper site for a subcutaneous injection.*

FDA Label Image

Fig 20 (Lanreotide Acetate 22)

An instructional illustration labeled Figure 15 showing a hand administering an injection in the upper arm area with a red X mark over the site, indicating this location is not recommended for injection.*

FDA Label Image

Fig 21 (Lanreotide Acetate 23)

An instructional illustration showing the proper technique for administering a subcutaneous injection using a syringe. The image emphasizes holding the syringe at a 90-degree angle to ensure the correct needle depth for deep subcutaneous injection, with a hand and a target injection site depicted.*

FDA Label Image

Fig 22 (Lanreotide Acetate 24)

Illustration showing a hand holding a syringe near a forearm with a large red X over the image, indicating that the injection should not be given in that area. Labeled as Figure 17, it demonstrates an incorrect subcutaneous injection site for Lanreotide Acetate.*

FDA Label Image

Fig 23 (Lanreotide Acetate 25)

Instructional diagram showing the correct subcutaneous injection technique for Lanreotide Acetate injection. It emphasizes the full retraction of the green needle shield and depicts the position of the plunger, green needle shield, and green collar during injection to ensure proper injection depth.*

FDA Label Image

Fig 24 (Lanreotide Acetate 26)

An instructional illustration showing how to hold and use a syringe for injection. The left part of the image shows a hand pressing down on the plunger of the syringe with an arrow indicating the motion, accompanied by a clock icon showing 20 seconds. The right part shows the syringe barrel held in position. This likely demonstrates the recommended injection technique or wait time for administration.*

FDA Label Image

Fig 25 (Lanreotide Acetate 27)

An instructional illustration showing a hand holding a syringe with a green needle shield labeled. The syringe is positioned above a skin surface, with an upward arrow indicating removal or withdrawal direction.*

FDA Label Image

Fig 26 (Lanreotide Acetate 28)

An instructional diagram showing a hand pressing a cotton ball or pad onto a spot on the skin, indicated by a downward arrow. This image likely demonstrates part of the procedure for applying or handling Lanreotide Acetate subcutaneous injection.*

FDA Label Image

Fig 27 (Lanreotide Acetate 29)

An instructional illustration showing a hand holding a Lanreotide Acetate injection device with an arrow pointing to the green cap labeled "Check here," likely indicating a step or area to verify before administration.*

FDA Label Image

Fig 28 (Lanreotide Acetate 30)

An instructional illustration showing a hand holding a syringe and inserting it into a container labeled 'SHARPS' with a biohazard symbol, depicting proper disposal of needle sharps.*

FDA Label Image

60 mg/0.2 mL Carton Label (Lanreotide Acetate 31)

Lanreotide Injection 60 mg/0.2 mL subcutaneous injection carton label from Cipla USA Inc. Includes directions for storage at 2°C to 8°C and advises administration by a healthcare professional. The package contains one pre-filled syringe and one safety needle. The label also features manufacturer information, a barcode, caution illustration, and contact details for questions.*

FDA Label Image

90 mg/0.3 mL Carton Label (Lanreotide Acetate 32)

Lanreotide Injection 90 mg/0.3 mL subcutaneous injection carton. The label indicates a single pre-filled syringe per box with storage instructions, dosage form, and manufacturer details (Pharmathen International, distributed by Cipla USA Inc.). It includes a warning not to touch the needle shield and a contact number for questions.*

FDA Label Image

120 mg/0.5 mL Carton Label (Lanreotide Acetate 33)

Lanreotide Injection 120 mg/0.5 mL carton packaging label for subcutaneous injection. The label states the product is a single-dose pre-filled syringe containing 120 mg lanreotide acetate per 0.5 mL, manufactured by Pharmathen International and labeled by Cipla USA Inc. It includes storage instructions (refrigerate at 2°C to 8°C) and cautions for use, with printed text emphasizing administration by a healthcare professional and to leave the syringe at room temperature for 30 minutes before injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.